cadonilimab

Hong Kong, April 20, 2026 In a significant breakthrough in oncology immunotherapy, Akeso, Inc. has announced promising Phase II...

Hong Kong, April 6, 2026 Promising Results in Immunotherapy-Resistant NSCLC In a significant advancement for lung cancer immunotherapy, Akeso,...